At a glance
| Product family | Cubicin; Cubicin RF |
|---|---|
| Class | Cyclic lipopeptide antibacterial |
| Clinical contexts | Selected skin and S. aureus bloodstream infections |
| Major exclusion | Not indicated for pneumonia |
| Monitoring focus | Muscle symptoms, creatine kinase, renal function |
Overview
Daptomycin is a bacterially derived cyclic lipopeptide developed as a systemic antibacterial medicine. Its peptide chemistry is part of a specialized antibacterial medicine, with no established role in cosmetic rejuvenation or sports recovery. The approved uses concern defined bacterial infections and age groups. Bloodstream infection also requires attention to its source, complications, and organism susceptibility; an antibiotic alone does not replace that assessment. Daptomycin’s noninferiority trial against standard therapy provides clinically relevant evidence, but the approved boundaries remain important. In particular, effectiveness against an organism in blood does not mean the drug will work at every anatomical site.
How it works
Daptomycin interacts with susceptible bacterial membranes in a calcium-dependent manner, disrupting membrane function and leading to bacterial death. Lung surfactant inhibits its antibacterial activity, which is a key reason the medicine is not indicated for pneumonia. This illustrates an important pharmacologic principle: laboratory susceptibility and a plausible mechanism still have to be interpreted in the actual tissue environment.
What the bloodstream-infection trial showed
A randomized study compared daptomycin with standard therapy in 246 patients with Staphylococcus aureus bacteremia, with or without endocarditis. The prespecified noninferiority criterion was met. Some microbiologic failures and reduced susceptibility occurred, emphasizing that clinical response and organism behavior still need follow-up rather than assuming an antibiotic guarantees clearance.
Supporting sources [2]
Important adverse effects
The label warns about myopathy and rhabdomyolysis, with creatine-kinase monitoring and attention to muscle symptoms. Eosinophilic pneumonia is another serious recognized reaction, despite pneumonia not being a treatment indication. Kidney function and concomitant medicines can affect treatment decisions. These risks are part of the benefit-risk assessment in serious infection.
Supporting sources [1]
Clinical evidence is site-specific
The medicine’s skin and bloodstream indications do not establish efficacy for every infection, left-sided endocarditis, or a noninfectious inflammatory condition. Culture results, the clinical syndrome, and source control matter. Its proven antibacterial role is best understood together with the infection-site and patient-population limitations described in the prescribing information.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Cyclic lipopeptide antibiotic.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Merck prescribing information: Cubicin (daptomycin) ↗Regulatory source · Checked 2026-10-27
- Daptomycin versus standard therapy for S. aureus bacteremia and endocarditis ↗Clinical trial source · Checked 2026-10-27